Background Polypharmacy is common in heart failure (HF), whereas its effect on adverse
outcomes in patients with HF with preserved ejection fraction (HFpEF) is unclear. Aim To …

Background: Polypharmacy is associated with a poor prognosis in the elderly, however,
information on the association of polypharmacy with cardiovascular outcomes in heart …

Polypharmacy, the use of 4 or more drugs, in patients with heart failure (HF) is universal.
Patients with HF with reduced ejection fraction (HFrEF) are prescribed combination therapy …

Heart failure (HF) affects over 6.5 million adults in the US1 and carries a survival
comparable to many cancers with~ 50% mortality at 5 years after diagnosis. 2 Almost half of …

Background: Hyperpolypharmacy is associated with adverse outcomes in older adults, but
because literature on its association with cardiovascular (CV) outcomes after acute …

Background Patients with heart failure are living longer with the inevitable morbidity of rising
medication counts. It remains uncertain what fraction of this ensuing polypharmacy exactly …

Backgrounds Drug treatments of heart failure with preserved ejection fraction (HFpEF) have
a little clinical benefit, but cardiovascular polypharmacy (CP) trend is observed in elderly …

Polypharmacy and heart failure are becoming increasingly common due to an ageing
population and the rise of multimorbidity. Treating heart failure necessitates prescribing of …

Background: Despite potential harm that can result from polypharmacy, real-world data on
polypharmacy in the setting of heart failure (HF) are limited. We sought to address this …

Background Comorbidity is common in heart failure, but previous prevalence estimates have
been based on a limited number of conditions using mainly non-primary care data sources …